1. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗